Efficacy and Tolerability of Enstilar® in Daily Practice

LEO Pharma

Status: Completed

Conditions: Plaque Psoriasis

Treatments: Drug: Enstilar®

Study type: Observational

Funder types: Industry

Identifiers

NCT02881346

NIS-ENSTILAR-1295

Details and patient eligibility

About

This study aims to assess how the Enstilar® aerosol foam performs in daily real-life practice with regards to effectiveness and convenience of application to psoriasis plaques on body and extremities. In addition the profiles of patients prescribed Enstilar® will be described, and preceeding, concomitant and follow-up management will be mapped. The study will be conducted in about 100 dermatology clinics all over Germany,

Enrollment: 410 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ≥ 18 years of age
• Psoriasis vulgaris
• Lesions on trunk and/or extremities of at least mild severity
• Treatment with Enstilar® planned
• Signed informed consent to participate

Exclusion criteria

• Enrolled in any interventional clinical trial
• Ongoing or recent treatment with any systemic psoriasis
• Ongoing or recent treatment with UV-therapy
• Ongoing or previous treatment with Enstilar®
• Psoriasis of scalp only
• Other forms of psoriasis, e.g. erythrodermic or pustular psoriasis
• More than 30% of surface area affected by psoriasis
• Any contraindications or known allergies to Enstilar® or its ingredients
• Incapacitated patients under institutionalized care

Trial design

410 participants in 1 patient group

Enstilar®

Description:

Patients with psoriasis vulgaris plaques on body and/or extremities will apply Enstilar® (calcipotriol /betamethasone dipropionate (50 micrograms/g + 0.5 mg/g) cutaneous foam) once daily for up to 4 weeks, according to the approved labelling of Enstilar® in Germany.

Treatment:

Drug: Enstilar®